Phoenix Financial Ltd. increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 18.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,105 shares of the pharmaceutical company’s stock after purchasing an additional 1,112 shares during the period. Phoenix Financial Ltd.’s holdings in Vertex Pharmaceuticals were worth $3,715,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of VRTX. Summit Global Investments bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth about $3,568,000. Danica Pension Livsforsikringsaktieselskab bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $13,823,000. UNIVEST FINANCIAL Corp bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $4,495,000. State Street Corp lifted its holdings in Vertex Pharmaceuticals by 1.2% in the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock worth $5,896,910,000 after purchasing an additional 141,320 shares during the last quarter. Finally, Meeder Advisory Services Inc. acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter worth approximately $3,187,000. 90.96% of the stock is owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Stock Performance
Vertex Pharmaceuticals stock opened at $538.60 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34. The business’s 50-day simple moving average is $522.37 and its 200-day simple moving average is $483.84. The firm has a market capitalization of $136.56 billion, a PE ratio of 34.66, a PEG ratio of 2.85 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 52 week low of $412.27 and a 52 week high of $568.67.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the prior year, the firm posted $4.80 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 11.8% on a year-over-year basis. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on VRTX shares. Sanford C. Bernstein raised Vertex Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, July 29th. TD Cowen lifted their price target on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a research report on Tuesday, November 3rd. Wells Fargo & Company boosted their price objective on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. Daiwa Securities Group boosted their price objective on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Leerink Partners started coverage on shares of Vertex Pharmaceuticals in a report on Monday, September 21st. They set an “outperform” rating and a $594.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $596.44.
Check Out Our Latest Stock Report on VRTX
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Recommended Stories
- Five stocks we like better than Vertex Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
